Final Results from ACIS Trial of Apalutamide Plus Abiraterone/Prednisone in Patients with Chemo-Naive mCRPC

Raoul S. Concepcion, MD, FACS

Raoul S. Concepcion, MD, FACS, presented “Final Results from ACIS Trial of Apalutamide Plus Abiraterone/Prednisone in Patients with Chemo-Naive mCRPC” during the 31st International Prostate Cancer Update in July 2021 in Snowbird, Utah.

How to cite: Concepcion, Raoul S. “Final Results from ACIS Trial of Apalutamide Plus Abiraterone/Prednisone in Patients with Chemo-Naive mCRPC.” July 2021. Accessed Jan 2026. https://grandroundsinurology.com/final-results-from-acis-trial-of-apalutamide-plus-abiraterone-prednisone-in-patients-with-chemo-naive-mcrpc/

Final Results from ACIS Trial of Apalutamide Plus Abiraterone/Prednisone in Patients with Chemo-Naive mCRPC – Summary#

Raoul S. Concepcion, MD, FACS, Chief Science Officer of U.S. Urology Partners in Nolensville, Tennessee, presents the final results of the ACIS trial, a random double-blind phase III study examining concomitant treatment with apalutamide and abiraterone plus prednisone against abiraterone and androgen deprivation therapy (ADT) in patients with chemotherapy-naïve metastatic castrate-resistant prostate cancer (mCRPC). He provides background, describes the study design and baseline characteristics, and reviews the findings. Dr. Concepcion explains the role of activated androgen receptors and intratumoral androgens in mCRPC. He also describes the concept of androgen annihilation, essentially blocking androgen at both the production and receptor level. The ACIS trial met its primary endpoint, radiographic progression-free survival (rPFS), at a median of 25.7 months of follow up, representing a 31% reduction in risk of radiographic progression or death. The risk reduction was maintained at 30% in long term follow-up at 54.8 months. However, overall survival was similar between treatment arms. Likewise, the secondary endpoints, time to initiation of cytotoxic chemotherapy, time to pain progression, and time to chronic opioid use, were also similar. Lastly, Dr. Concepcion notes that no new safety signals were observed and patient quality of life was comparable between treatment arms.

About The 31st Annual International Prostate Cancer Update:#

The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. Dr. Concepcion delivered this educational activity during the 31st iteration of the meeting in July 2021 in Snowbird, Utah.

ABOUT THE AUTHOR

Raoul S. Concepcion, MD, FACS

Raoul S. Concepcion, MD, FACS, is the Chief Science Officer of U.S. Urology Partners in Nolensville, Tennessee, where he is developing a precision medicine comprehensive cancer program centered on genomic testing, pathway development, data aggregation, and clinical trial work. He is additionally a co-founder and the CEO of UroVault in Nashville, Tennessee. Dr. Concepcion has served as a founding member and former president of the Large Urology Group Practice Association (LUGPA), the premier nonprofit association and advocate for independent urology practices. He is certified by the American Urological Association (AUA) and is a member of that organization, as well as the Southeastern Section of the AUA, Society of Urologic Oncology, American College of Surgeons, and the Nashville Surgical Society.

About The Author

Raoul S. Concepcion, MD, FACS

Raoul S. Concepcion, MD, FACS, is the Chief Science Officer of U.S. Urology Partners in Nolensville, Tennessee, where he is developing a precision medicine comprehensive cancer program centered on genomic testing, pathway development, data aggregation, and clinical trial work. He is additionally a co-founder and the CEO of UroVault in Nashville, Tennessee. Dr. Concepcion has served as a founding member and former president of the Large Urology Group Practice Association (LUGPA), the premier nonprofit association and advocate for independent urology practices. He is certified by the American Urological Association (AUA) and is a member of that organization, as well as the Southeastern Section of the AUA, Society of Urologic Oncology, American College of Surgeons, and the Nashville Surgical Society. Dr. Concepcion completed his residency in general surgery and urology at Vanderbilt University in Nashville, Tennessee, where he was Chief Urology Resident, and later served as a Clinical Associate Professor of Urology. Additionally, he was a research fellow in the Light Laboratories at Vanderbilt. More recently, he has completed the City of Hope Intensive Course on Cancer Risk Assessment for hereditary cancer and genomic testing. Dr. Concepcion has been in practice since 1990 and has been the principal or co-principal investigator on many clinical trials since then. His clinical interests focus on advanced prostate and bladder cancer and lower urinary tract reconstruction, as well as the role of genomics and genetic testing in GU tumors. Dr. Concepcion co-founded CUSP, a urologic research consortium in the United States that specializes in site and patient accrual for the pharmaceutical and biolab industries. Additionally, he is an advisor and/or speaker for many companies, including Dendreon, Pfizer, Astellas, Amgen, Cellay, and Janssen, and has served as editor for Urologists in Cancer Care.

Share This

Chat with usLiveChat